Department of Cell Biology, University of Groningen, University Medical Center Groningen, AV Groningen, The Netherlands.
Interfaculty Institute of Cell Biology, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Autophagy. 2022 Jan;18(1):50-72. doi: 10.1080/15548627.2021.1895658. Epub 2021 Apr 2.
Autophagic pathways cross with lipid homeostasis and thus provide energy and essential building blocks that are indispensable for liver functions. Energy deficiencies are compensated by breaking down lipid droplets (LDs), intracellular organelles that store neutral lipids, in part by a selective type of autophagy, referred to as lipophagy. The process of lipophagy does not appear to be properly regulated in fatty liver diseases (FLDs), an important risk factor for the development of hepatocellular carcinomas (HCC). Here we provide an overview on our current knowledge of the biogenesis and functions of LDs, and the mechanisms underlying their lysosomal turnover by autophagic processes. This review also focuses on nonalcoholic steatohepatitis (NASH), a specific type of FLD characterized by steatosis, chronic inflammation and cell death. Particular attention is paid to the role of macroautophagy and macrolipophagy in relation to the parenchymal and non-parenchymal cells of the liver in NASH, as this disease has been associated with inappropriate lipophagy in various cell types of the liver.: ACAT: acetyl-CoA acetyltransferase; ACAC/ACC: acetyl-CoA carboxylase; AKT: AKT serine/threonine kinase; ATG: autophagy related; AUP1: AUP1 lipid droplet regulating VLDL assembly factor; BECN1/Vps30/Atg6: beclin 1; BSCL2/seipin: BSCL2 lipid droplet biogenesis associated, seipin; CMA: chaperone-mediated autophagy; CREB1/CREB: cAMP responsive element binding protein 1; CXCR3: C-X-C motif chemokine receptor 3; DAGs: diacylglycerols; DAMPs: danger/damage-associated molecular patterns; DEN: diethylnitrosamine; DGAT: diacylglycerol O-acyltransferase; DNL: lipogenesis; EHBP1/NACSIN (EH domain binding protein 1); EHD2/PAST2: EH domain containing 2; CoA: coenzyme A; CCL/chemokines: chemokine ligands; CCl carbon tetrachloride; ER: endoplasmic reticulum; ESCRT: endosomal sorting complexes required for transport; FA: fatty acid; FFAs: free fatty acids; FFC: high saturated fats, fructose and cholesterol; FGF21: fibroblast growth factor 21; FITM/FIT: fat storage inducing transmembrane protein; FLD: fatty liver diseases; FOXO: forkhead box O; GABARAP: GABA type A receptor-associated protein; GPAT: glycerol-3-phosphate acyltransferase; HCC: hepatocellular carcinoma; HDAC6: histone deacetylase 6; HECT: homologous to E6-AP C-terminus; HFCD: high fat, choline deficient; HFD: high-fat diet; HSCs: hepatic stellate cells; HSPA8/HSC70: heat shock protein family A (Hsp70) member 8; ITCH/AIP4: itchy E3 ubiquitin protein ligase; KCs: Kupffer cells; LAMP2A: lysosomal associated membrane protein 2A; LDs: lipid droplets; LDL: low density lipoprotein; LEP/OB: leptin; LEPR/OBR: leptin receptor; LIPA/LAL: lipase A, lysosomal acid type; LIPE/HSL: lipase E, hormone sensitive type; LIR: LC3-interacting region; LPS: lipopolysaccharide; LSECs: liver sinusoidal endothelial cells; MAGs: monoacylglycerols; MAPK: mitogen-activated protein kinase; MAP3K5/ASK1: mitogen-activated protein kinase kinase kinase 5; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MCD: methionine-choline deficient; MGLL/MGL: monoglyceride lipase; MLXIPL/ChREBP: MLX interacting protein like; MTORC1: mechanistic target of rapamycin kinase complex 1; NAFLD: nonalcoholic fatty liver disease; NAS: NAFLD activity score; NASH: nonalcoholic steatohepatitis; NPC: NPC intracellular cholesterol transporter; NR1H3/LXRα: nuclear receptor subfamily 1 group H member 3; NR1H4/FXR: nuclear receptor subfamily 1 group H member 4; PDGF: platelet derived growth factor; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PLIN: perilipin; PNPLA: patatin like phospholipase domain containing; PNPLA2/ATGL: patatin like phospholipase domain containing 2; PNPLA3/adiponutrin: patatin like phospholipase domain containing 3; PPAR: peroxisome proliferator activated receptor; PPARA/PPARα: peroxisome proliferator activated receptor alpha; PPARD/PPARδ: peroxisome proliferator activated receptor delta; PPARG/PPARγ: peroxisome proliferator activated receptor gamma; PPARGC1A/PGC1α: PPARG coactivator 1 alpha; PRKAA/AMPK: protein kinase AMP-activated catalytic subunit; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; PTEN: phosphatase and tensin homolog; ROS: reactive oxygen species; SE: sterol esters; SIRT1: sirtuin 1; SPART/SPG20: spartin; SQSTM1/p62: sequestosome 1; SREBF1/SREBP1c: sterol regulatory element binding transcription factor 1; TAGs: triacylglycerols; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: transcription factor EB; TGFB1/TGFβ: transforming growth factor beta 1; Ub: ubiquitin; UBE2G2/UBC7: ubiquitin conjugating enzyme E2 G2; ULK1/Atg1: unc-51 like autophagy activating kinase 1; USF1: upstream transcription factor 1; VLDL: very-low density lipoprotein; VPS: vacuolar protein sorting; WIPI: WD-repeat domain, phosphoinositide interacting; WDR: WD repeat domain.
自噬途径与脂质稳态交叉,因此提供了不可缺少的能量和基本构建块,这些都是肝脏功能所必需的。通过分解脂滴(LDs)来补偿能量不足,LDs 是储存中性脂质的细胞内细胞器,部分通过一种称为脂噬的选择性自噬类型。脂噬的过程似乎在脂肪性肝病(FLD)中没有得到适当的调节,FLD 是肝细胞癌(HCC)发展的一个重要危险因素。本文综述了我们目前对 LD 的生物发生和功能以及自噬过程介导的溶酶体转化的机制的了解。这篇综述还重点介绍了非酒精性脂肪性肝炎(NASH),这是一种以脂肪变性、慢性炎症和细胞死亡为特征的特定类型的 FLD。特别关注巨自噬和巨脂噬在 NASH 中与肝实质细胞和非实质细胞的关系,因为这种疾病与各种肝细胞类型中的不适当脂噬有关。ACAT:乙酰辅酶 A 乙酰基转移酶;ACAC/ACC:乙酰辅酶 A 羧化酶;AKT:AKT 丝氨酸/苏氨酸激酶;ATG:自噬相关;AUP1:AUP1 脂质调节 VLDL 组装因子的液滴;BSCL2/Seipin:BSCL2 脂质生成相关的液滴生物发生,Seipin;CMA:伴侣介导的自噬;CREB1/CREB:cAMP 反应元件结合蛋白 1;CXCR3:C-X-C 基序趋化因子受体 3;DAGs:二酰甘油;DAMPs:危险/损伤相关分子模式;DEN:二乙基亚硝胺;DGAT:二酰甘油 O-酰基转移酶;DNL: 脂肪生成;EHBP1/NACSIN(EH 结构域结合蛋白 1);EHD2/PAST2:EH 结构域包含 2;CoA:辅酶 A;CCL/chemokines:趋化因子配体;CCl 碳四氯化物;ER:内质网;ESCRT:内体分选复合物需要运输;FA:脂肪酸;FFAs:游离脂肪酸;FFC:高饱和脂肪、果糖和胆固醇;FGF21:成纤维细胞生长因子 21;FITM/FIT:脂肪储存诱导跨膜蛋白;FLD:脂肪性肝病;FOXO:叉头框 O;GABARAP:GABA 型 A 受体相关蛋白;GPAT:甘油-3-磷酸酰基转移酶;HCC:肝细胞癌;HDAC6:组蛋白去乙酰化酶 6;HECT:同源物 E6-AP C 末端;HFCD:高脂肪、胆碱缺乏;HFD:高脂肪饮食;HSCs:肝星状细胞;HSPA8/HSC70:热休克蛋白家族 A(Hsp70)成员 8;ITCH/AIP4:痒 E3 泛素蛋白连接酶;KCs:库普弗细胞;LAMP2A:溶酶体相关膜蛋白 2A;LDs:脂滴;LDL:低密度脂蛋白;LEP/OB:瘦素;LEPR/OBR:瘦素受体;LIPA/LAL:脂肪酶 A,溶酶体酸性类型;LIPE/HSL:脂肪酶 E,激素敏感型;LIR:LC3 相互作用区;LPS:脂多糖;LSECs:肝窦内皮细胞;MAGs:单酰甘油;MAPK:丝裂原激活蛋白激酶;MAP3K5/ASK1:丝裂原激活蛋白激酶激酶激酶 5;MAP1LC3/LC3:微管相关蛋白 1 轻链 3;MCD:蛋氨酸-胆碱缺乏;MGLL/MGL:单甘油酯脂肪酶;MLXIPL/ChREBP:MLX 相互作用蛋白样;MTORC1:雷帕霉素激酶复合物 1 的机制靶标;NAFLD:非酒精性脂肪性肝病;NAS:NAFLD 活动评分;NASH:非酒精性 steatohepatitis;NPC:NPC 细胞内胆固醇转运蛋白;NR1H3/LXRα:核受体亚家族 1 组 H 成员 3;NR1H4/FXR:核受体亚家族 1 组 H 成员 4;PDGF:血小板衍生生长因子;PI3K3/VPS34:磷脂酰肌醇 3-激酶催化亚基 3;PLIN:脂滴蛋白;PNPLA:patatin 样磷脂酶结构域包含;PNPLA2/ATGL:patatin 样磷脂酶结构域包含 2;PNPLA3/Adiponutrin:patatin 样磷脂酶结构域包含 3;PPAR:过氧化物酶体增殖物激活受体;PPARA/PPARα:过氧化物酶体增殖物激活受体 alpha;PPARD/PPARδ:过氧化物酶体增殖物激活受体 delta;PPARG/PPARγ:过氧化物酶体增殖物激活受体 gamma;PPARGC1A/PGC1α:PPARG 共激活因子 1alpha;PRKAA/AMPK:蛋白激酶 AMP 激活的催化亚基;PtdIns3K:III 类磷酸肌醇 3-激酶;PtdIns3P:磷脂酰肌醇-3-磷酸;PTEN:磷酸酶和张力蛋白同源物;ROS:活性氧;SE:甾醇酯;SIRT1:沉默调节蛋白 1;SPART/SPG20:Spartin;SQSTM1/p62:自噬体 1;SREBF1/SREBP1c:固醇调节元件结合转录因子 1;TAGs:三酰甘油;TFE3:转录因子结合 IGHM 增强子 3;TFEB:转录因子 EB;TGFB1/TGFβ:转化生长因子 beta 1;Ub:泛素;UBE2G2/UBC7:泛素缀合酶 E2 G2;ULK1/Atg1:UNC-51 样自噬激活激酶 1;USF1:上游转录因子 1;VLDL:极低密度脂蛋白;VPS:液泡蛋白分选;WIPI:WD 重复域,磷酸肌醇相互作用;WDR:WD 重复域。